Showing results (501-510 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 21, 2017
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumorsGlen J Weiss, Gayle Jameson, Daniel D Von Hoff, et al.
Investigational New Drugs|July 23, 2017
Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity statusMohamed Wehbe, Cody Lo, Ada W Y Leung, et al.
Investigational New Drugs|July 23, 2017
Induction of accelerated senescence by the microtubule-stabilizing agent peloruside AAriane Chan, Connie Gilfillan, Nikki Templeton, et al.
Investigational New Drugs|September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumorsSandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.
Investigational New Drugs|November 20, 2015
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignanciesJoleen M Hubbard, George Kim, Mitesh J Borad, et al.
Investigational New Drugs|December 3, 2015
Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumorsSanjay Goel, Santiago Viteri, Teresa Morán, et al.
Investigational New Drugs|November 18, 2015
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding siteDiane-Charlotte Imbs, Marie-Noelle Paludetto, Sylvie Négrier, et al.
Investigational New Drugs|April 1, 1989
Clinical trials with fluorinated pyrimidines in patients with head and neck cancerM al-Sarraf
Investigational New Drugs|November 28, 2015
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor modelsDarlene Barnard, H Bruce Diaz, Teresa Burke, et al.
Investigational New Drugs|November 19, 2017
The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing's sarcoma cell lineChristian Marx, Lisa Marx-Blümel, Nora Lindig, et al.
Pageof 372